Bevacizumab Biosimilar Vial for Oncology from China
Bevacizumab, an Avastin biosimilar, is a VEGF monoclonal antibody supplied in 100 mg/4 ml vials for retail infusion in oncology. It modulates angiogenesis through immune regulation. This immunological product, in measured doses for retail sale, is classified under tariff item 3002.15.00.
Duty Rate — China → Canada
0%
Import Tips
• Verify that the vials are labelled for retail sale and include the proper DIN
• Submit a valid import permit from Health Canada for biologics
• Keep batch records to prove the product is an immunological product under Chapter 30